Ipilimumab-induced orbital inflammation resembling graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression

Ophthalmic Plastic and Reconstructive Surgery

Volumn 30, Issue 1, 2014, Pages 83-

  Borodic, Gary E ^a   Hinkle, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; LIOTHYRONINE; THYROGLOBULIN ANTIBODY; THYROID ANTIBODY; THYROID PEROXIDASE ANTIBODY;

ANXIETY; DIARRHEA; DISEASE COURSE; GRAVES DISEASE; HEART PALPITATION; HEAT INTOLERANCE; HUMAN; HYPERTHYROIDISM; LETHARGY; LETTER; LIOTHYRONINE BLOOD LEVEL; ORBIT INFLAMMATION; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; GRAVES DISEASE; HUMANS; HYPERTHYROIDISM; NEOPLASMS, UNKNOWN PRIMARY; ORBITAL MYOSITIS;

EID: 84893054291     PISSN: 07409303     EISSN: 15372677     Source Type: Journal    
DOI: 10.1097/IOP.0000000000000033     Document Type: Letter

References (4)

1. Borodic G, Hinkle DM, Cia Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg 2011;27:e87-8.
2. Borodic GE, Hinkle DM. Reply Re: "Drug-induced Graves disease from CTLA-4 receptor sup pression." Ophthal Plast Reconstr Surg 2013;29:241.
3. Sohrab MA, Desai RU, Chambers CB, et al. Re: "Drug-induced Graves disease from CTLA-4 receptor suppression." Ophthal Plast Reconstr Surg 2013;29:239-40.
4. Lecouflet M, Verschoore M, Giard C, et al. Orbital myositis associated with ipilimumab. Ann Dermatol Venereol 2013;140:448-51.